Skip to main content
    A

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $21.23
    -0.15 (-0.70%)

    Market Cap: $7.45B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.24, above the $0.23 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    +18.04%
    Streak
    7 Q

    Upcoming Estimates

    Reports Feb 25, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.24
    Range$0.22 - $0.26
    9 analysts
    Revenue Consensus
    $860.29M
    Range$810.32M - $899.85M
    8 analysts
    Reports Apr 29, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.26
    Range$0.24 - $0.28
    5 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.26+1.2%
    60d ago$0.26+1.2%
    30d ago$0.25+3.5%
    7d ago$0.25+3.5%
    Current$0.26
    Revenue Consensus
    $799.45M
    Range$769.30M - $836.10M
    4 analysts

    Next Report

    AMRX has an expected report date of Feb 25, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 14.3% above the $0.21 reported for the quarter ended Dec 31, 2025.

    AMRX Earnings Call

    The latest AMRX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, AMRX beat 29, missed 8 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $862.68M, up 10.0% from $784.51M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.24$0.23$0.20 - $0.28+4.35%Beat+41.2%70 up, 1 downNov 3, 2026$862.68M
    Jun 30, 2026$0.27$0.24$0.20 - $0.26+12.50%Beat+8.0%52 up, 1 downJul 30, 2026$796.20M
    Mar 31, 2026$0.27$0.19$0.15 - $0.19+38.96%Beat+28.6%51 up, 0 downMay 7, 2026$722.52M
    Dec 31, 2025$0.21$0.18$0.16 - $0.20+16.67%Beat+75.0%51 up, 0 downFeb 27, 2026$814.32M
    Sep 30, 2025$0.17$0.14$0.09 - $0.17+21.43%Beat+6.3%41 up, 2 downOct 30, 2025$784.51M
    Jun 30, 2025$0.25$0.17$0.16 - $0.20+47.06%Beat+56.3%41 up, 0 downAug 5, 2025$724.51M
    Mar 31, 2025$0.21$0.15$0.13 - $0.16+40.00%Beat+50.0%30 up, 1 downMay 2, 2025$695.42M
    Dec 31, 2024$0.12$0.15$0.15 - $0.16-20.00%Miss-14.3%41 up, 1 downFeb 28, 2025$730.52M
    Sep 30, 2024$0.16$0.14$0.12 - $0.15+14.29%Beat-15.8%41 up, 0 downNov 8, 2024$702.47M
    Jun 30, 2024$0.16$0.14$0.12 - $0.17+14.29%Beat-15.8%41 up, 0 downAug 9, 2024$701.78M
    Mar 31, 2024$0.14$0.09$0.08 - $0.11+55.56%Beat+16.7%50 up, 0 downMay 3, 2024$659.19M
    Dec 31, 2023$0.14$0.09$0.07 - $0.15+55.56%Beat-39.1%50 up, 0 downMar 1, 2024$616.98M
    Sep 30, 2023$0.19$0.13$0.09 - $0.14+46.15%Beat+35.7%51 up, 0 downNov 7, 2023$620.04M
    Jun 30, 2023$0.19$0.10$0.07 - $0.14+90.00%Beat0.0%50 up, 0 downAug 4, 2023$599.05M
    Mar 31, 2023$0.12$0.10$0.09 - $0.10+20.00%Beat0.0%52 up, 0 downMay 5, 2023$557.54M
    Dec 31, 2022$0.23$0.21$0.19 - $0.22+9.52%Beat+27.8%70 up, 0 downMar 2, 2023$609.76M
    Sep 30, 2022$0.14$0.18$0.14 - $0.20-22.22%Miss-33.3%70 up, 1 downNov 4, 2022$545.56M
    Jun 30, 2022$0.19$0.19$0.18 - $0.210.00%In line-24.0%70 up, 1 downAug 5, 2022$559.36M
    Mar 31, 2022$0.12$0.13$0.11 - $0.14-7.69%Miss-40.0%70 up, 1 downMay 4, 2022$497.63M
    Dec 31, 2021$0.18$0.20$0.17 - $0.22-10.00%Miss+28.6%70 up, 0 downMar 2, 2022$536.90M
    Sep 30, 2021$0.21$0.20$0.18 - $0.24+5.00%Beat+31.2%7N/ANov 3, 2021$528.59M
    Jun 30, 2021$0.25$0.18$0.17 - $0.20+38.89%Beat+92.3%8N/AAug 9, 2021$535.08M
    Mar 31, 2021$0.20$0.18$0.15 - $0.20+11.11%Beat0.0%11N/AMay 7, 2021$493.11M
    Dec 31, 2020$0.14$0.13$0.10 - $0.16+7.69%Beat+75.0%11N/AFeb 26, 2021$510.03M
    Sep 30, 2020$0.16$0.12$0.10 - $0.13+33.33%Beat+300.0%11N/ANov 6, 2020$519.29M
    Jun 30, 2020$0.13$0.10$0.06 - $0.11+30.00%Beat+44.4%12N/AAug 6, 2020$464.66M
    Mar 31, 2020$0.20$0.09$0.05 - $0.14+122.22%Beat+42.9%11N/AMay 11, 2020$498.53M
    Dec 31, 2019$0.08$0.05$0.02 - $0.09+60.00%Beat-75.8%11N/AFeb 26, 2020$397.33M
    Sep 30, 2019$0.04$0.13$0.10 - $0.28-69.23%Miss-85.7%13N/ANov 6, 2019$378.28M
    Jun 30, 2019$0.09$0.12$0.05 - $0.27-25.00%Miss-62.5%12N/AAug 5, 2019$404.64M
    Mar 31, 2019$0.14$0.18$0.12 - $0.21-22.22%Miss0.0%11N/AMay 9, 2019$446.12M
    Dec 31, 2018$0.33$0.27$0.24 - $0.34+22.22%Beat+200.0%11N/AFeb 28, 2019$497.53M
    Sep 30, 2018$0.28$0.27$0.26 - $0.29+3.70%Beat+21.7%13N/ANov 7, 2018$476.49M
    Jun 30, 2018$0.24$0.22$0.17 - $0.27+9.09%Beat+33.3%15N/AAug 9, 2018$413.79M
    Mar 31, 2018$0.14$0.10N/A+40.00%Beat+27.3%N/AN/AMay 7, 2018$275.19M
    Dec 31, 2017$0.11$0.11N/A0.00%In line-31.3%N/AN/AMar 1, 2018$293.37M
    Sep 30, 2017$0.23$0.20N/A+15.00%Beat-37.8%N/AN/ANov 9, 2017$254.73M
    Jun 30, 2017$0.18$0.14N/A+28.57%Beat-14.3%N/AN/AAug 9, 2017$259.87M
    Mar 31, 2017$0.11$0.13N/A-15.38%Miss-74.4%N/AN/AMay 10, 2017$225.68M
    Dec 31, 2016$0.16$0.16N/A0.00%In line-74.2%N/AN/AMar 1, 2017$298.58M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.84, up 44.8% from the year before. It was $1.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.84+44.8%
    Dec 31, 2024$0.58-9.4%
    Dec 31, 2023$0.64N/A
    Dec 31, 2022$0.68-19.0%
    Dec 31, 2021$0.84+33.3%
    Dec 31, 2020$0.63+80.0%
    Dec 31, 2019$0.35-64.6%
    Dec 31, 2018$0.99+57.1%
    Dec 31, 2017$0.63-46.2%
    Dec 31, 2016$1.17N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,35112
    2026Q2Jun 30, 20264,82510
    2026Q1Mar 31, 20265,89911
    2025Q4Dec 31, 20255,54710
    2025Q3Sep 30, 20254,6489
    2025Q2Jun 30, 20255,34910
    2025Q1Mar 31, 20254,5528
    2024Q4Dec 31, 20245,77611

    2026Q3 Earnings Call

    Opening remarks

    Tony DiMeo Head of Investor Relations Good morning, and thank you for joining Amneal Pharmaceuticals Third Quarter 2026 Earnings Call. Today, we issued a press release reporting Q3 results. The earnings press release and presentation are available on the IR page of amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the sections entitled "Cautionary Statements on Forward-Looking Statements" in our press release and presentation for factors that may impact future performance. We also discuss non-GAAP measures. Information on the use of these measures and reconciliations to GAAP are in the earnings release and presentation. On the call today are Chirag and Chintu Patel, co-founders and co-CEOs, Tasos Konidaris, CFO, Joe Renda for specialty, and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag.

    Chirag Patel Co-CEO Thank you, Tony. Good morning, everyone. Today, Amneal is a stronger, more diversified company than ever before, with a portfolio focused on high-value products designed to drive durable growth. We've expanded across specialty, biosimilars, and complex products while building the capabilities and capacity to drive these businesses long term. 2026 marks our seventh consecutive year of top- and bottom-line growth, a track record that stands out in the industry. Our third-quarter performance reflects that progress, with revenue of $863 million, up 10%, adjusted EBITDA of $207 million, up 30%, and adjusted EPS of $0.26, up 53%. The breadth of our portfolio and the depth of our pipeline give us confidence that we are still early in realizing Amneal's full potential. Let me highlight the progress across our key growth areas. First, in biosimilars, we closed the Kashiv transaction in Q3. Amneal now has the end-to-end capabilities to succeed in biosimilars, with R&D, manufacturing, and commercial capabilities in-house. Now it is all about execution. From a macro perspective, we have access to a large and growing biosimilar market, with approximately $234 billion of U.S. biologic sales losing exclusivity over the next decade. At the same time, streamlined regulatory pathways, new commercial models such as private labels, and accelerating market adoption are creating a major inflection point for the U.S. biosimilar industry. Against this backdrop, our portfolio strategy is deliberately differentiated, balancing targeted lower-competition molecules with a select number of broader biologic opportunities. We believe this approach positions Amneal to capture attractive economics and sustain long-term value creation. For Amneal, biosimilars are a natural extension of our purpose: making key medicines more accessible and affordable while building a durable growth platform. Biologics account for more than half of U.S.

    Frequently Asked Questions About AMRX

    When is Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings date?

    Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings report is expected for Feb 25, 2027.

    Did AMRX beat earnings estimates last quarter?

    Yes. Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.24 for the quarter ended Sep 30, 2026, above the $0.23 estimate, a 4.35% surprise.

    What EPS do analysts expect from AMRX next quarter?

    The consensus EPS estimate for Amneal Pharmaceuticals, Inc. Class A Common Stock for the quarter ending Dec 31, 2026 is $0.24 from 9 analysts, with estimates from $0.22 to $0.26.

    How often does AMRX beat earnings estimates?

    Amneal Pharmaceuticals, Inc. Class A Common Stock beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +20.12%.